Lipaglyn™, is a novel drug targeted at bridging an unmet healthcare need for treating
Diabetic Dyslipidemia or Hypertriglyceridemia in type 2 diabetes, not controlled by
statins alone. The drug has been approved for launch in India by the Drug Controller
General of India (DCGI). With a novel action that offers lipid and glucose lowering
effects in one molecule, Lipaglyn™ is the first Glitazar to be approved anywhere in
the world.
If you are an adult suffering from Type-2 diabetes and from hypertriglyceridemia, this
novel therapy could work for you.
Lipaglyn is a prescription drug authorised for sale in India only and can be taken only under the advice and guidance of a registered medical practitioner.
Contact your physician for more information.
